GANX
Gain Therapeutics, Inc.
Key Financials
EPS (Diluted)
$-0.61
↑ 31.5%
Operating Income
$-18710702
↑ 8.1%
Revenue
$55180
0.0%
Net Income
$-20161099
↑ 1.2%
Total Liabilities
$4.3M
↓ 11.1%
Total Assets
$22.8M
↑ 88.2%
Long-term Debt
$400953.00
↓ 8.6%
Operating Cash Flow
$-18465432.00
↑ 2.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 3/26/2026 | View on SEC |
| 4 | 3/26/2026 | View on SEC |
| 10-K | 3/26/2026 | View on SEC |
| 8-K | 3/26/2026 | View on SEC |
| 8-K | 3/18/2026 | View on SEC |
| 8-K | 2/3/2026 | View on SEC |
| 8-K | 12/18/2025 | View on SEC |
| S-8 | 12/3/2025 | View on SEC |
| 8-K | 11/28/2025 | View on SEC |
| 424B5 | 11/28/2025 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | GANX |
| Company Name | Gain Therapeutics, Inc. |
| CIK | 1819411 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (301) 500-1556 |